SCM
PBMWW

Shaolin Capital Management’s Psyence Biomedical Warrant PBMWW Stock Holding History

Shaolin Capital Management’s Portfolio PBMWW Stock Details PBMWW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-148,809
Closed -$1.88K – 247
2024
Q3 		$1.88K Sell
148,809
-26,191
-15% -$458 ﹤0.01% 265
2024
Q2 		$1.84K Hold
175,000
– – ﹤0.01% 344
2024
Q1 		$12.2K Buy
+175,000
New +$10.9K ﹤0.01% 274

Other funds holding PBMWW

HCI
Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

Shaolin Capital Management's PBMWW Position: Q4 2024 in Review

Shaolin Capital Management sold out of Psyence Biomedical Warrant (PBMWW) in Q4 2024, closing a stake of 148,809 shares — an estimated $1.88K sold.

Shaolin Capital Management first reported a position in PBMWW in Q1 2024 and held it in 3 quarters. The position peaked at $12.2K in Q1 2024. 22 funds tracked by Wall St. Rank hold PBMWW as of Q4 2024.

  • Shaolin Capital Management reported no remaining Psyence Biomedical Warrant position as of Q4 2024 after selling out during the quarter.
  • Shaolin Capital Management sold 148,809 Psyence Biomedical Warrant shares in Q4 2024, an estimated $1.88K.
  • Shaolin Capital Management first reported a position in Psyence Biomedical Warrant in Q1 2024 and held it in 3 quarters.
  • Shaolin Capital Management's Psyence Biomedical Warrant position peaked at $12.2K in Q1 2024.
  • 22 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q4 2024.

Based on Shaolin Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.